

Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons

Robert M. Grant, MD, MPH

Frederick M. Hecht, MD

Maria Warmerdam, BS

Lea Liu, MD, MSc

Teri Liegler, PhD

Christos J. Petropoulos, PhD

Nicholas S. Hellmann, MD

Margaret Chesney, PhD

Michael P. Busch, MD

James O. Kahn, MD

P RIMARY HIV-1 (HUMAN IMMUNODEFICIENCY virus type 1) resistance to antiretroviral drugs has been reported.¹⁻¹⁰ The proportion of recently infected individuals who acquire HIV-1 that is resistant to 2 or more classes of antiretroviral drugs is 2.7% (1/37) in San Francisco,⁴ 2.9% (2/70) in Geneva,¹⁰ 3.8% (3/80) in New York City,⁸ and 1.4% (2/141) in Los Angeles, San Diego, Boston, and Denver.⁹ The potential for epidemic spread of resistant HIV-1 is difficult to assess because surveillance is limited to small numbers of participants at each geographic location and short duration of observation. In this study, we monitored recently infected and drug-naïve individuals in San Francisco from June 1996 through June 2001 to assess time trends in primary drug resistance in a community with widespread use of anti-HIV therapies and where virologic drug failure is common.^{11,12}

The clinical significance of primary drug resistance is determined by its prevalence and its implications for virologic and immunologic outcomes. Observa-

Context Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy.

Objective To determine trends in prevalence of HIV-1 drug resistance among recently infected individuals in a geographic area with a high penetration of antiviral treatment.

Design, Setting, and Patients Consecutive case series of 225 patients referred to a San Francisco, Calif, hospital with recent HIV-1 infection from June 1996 through June 2001.

Main Outcome Measure Time trends in the prevalence of genotypic and phenotypic primary drug resistance.

Results Mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) steadily increased from 0% in 1996-1997 to 12 (13.2%) in 2000-2001 ($P=.01$). There was 1 mutation associated with protease inhibitor resistance in 1996-1997 (2.5%) and there were 7 (7.7%) in 2000-2001 ($P=.25$). Genotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) initially decreased and then returned to prior levels ($P=.007$ for test of homogeneity). Genotypic resistance to 2 or more classes of drugs increased from 1 (2.5%) to 12 (13.2%) ($P=.004$), but only 1 infection (1.2%) in the latter period was resistant to all 3 classes of agents ($P=.58$). Primary phenotypic resistance decreased for NRTIs from 21% to 6.2% ($P=.03$) and increased for NNRTIs from 0 to 8 (9.9%) ($P=.02$). Phenotypic resistance increased for protease inhibitors from 2.6% to 6.2% ($P=.32$). Median time to virologic suppression (<500 copies/mL) during therapy was 12 weeks for patients with genotypic evidence of resistance compared with 5 weeks for patients with drug-sensitive infections ($P=.02$).

Conclusions The frequency of primary resistance to NNRTIs is increasing, although resistance to all available classes of antiretroviral therapy remains rare. Genotypic resistance testing in recently infected persons predicts time to viral suppression during therapy.

JAMA. 2002;288:181-188

www.jama.com

tions of drug-treated patients indicate that drug-resistant infection is associated with virologic failure during combination therapy, but CD4 cell counts are often relatively preserved,¹³ and clinical disease progression may be substantially delayed.¹⁴ Individuals recently infected with drug-resistant HIV-1 offer unique opportunities to study the effects of drug resistance on CD4 T-cell counts and treatment responses in participants without prior exposure to antiretroviral therapy.

METHODS

Study Population

Consecutive participants with evidence of acute or recent HIV-1 infec-

tion in the San Francisco Bay area were enrolled in the Options Project at San Francisco General Hospital. Participants were recruited through referrals from physicians, HIV-1 testing and counseling sites, community-based organizations, community health centers, and self-referral. Individuals at risk for HIV-1 infection and complaining of 2 or more symptoms of acute infection and asymptomatic individuals with recent receptive anal sex with a known

Author Affiliations and Financial Disclosures are listed at the end of this article.

Corresponding Author and Reprints: Robert M. Grant, MD, MPH, Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141 (e-mail: rgrant@itsa.ucsf.edu).

See also pp 169 and 239.

HIV-1–infected partner were eligible to receive laboratory screening for acute HIV-1 infection.

Participants were eligible for this study if they met 1 of the following criteria for recent HIV infection at specimen collection for resistance testing: (1) detectable HIV-1 RNA in blood plasma and a negative or indeterminate Western blot assay for anti-HIV-1 antibodies, with subsequent antibody seroconversion on follow-up; (2) a positive enzyme immunoassay (EIA) with Western blot confirmation within 12 months of a documented negative HIV-1 antibody result; or (3) an optical density signal-to-cutoff ratio of less than 0.75 according to a less sensitive and stan-

dard dual EIA testing system,¹⁵ provided there was a history compatible with recent HIV infection and a CD4 cell count higher than 200/μL.

Participants were excluded from the analysis of primary resistance if they had received antiretroviral therapy for more than 7 days before blood collection for resistance testing. The study was approved by the University of California, San Francisco, institutional review board, and written informed consent was obtained from all study participants.


Genotypic Assessment

Genotypic resistance is defined as the presence of viral mutations associated

with impaired drug susceptibility or virologic response as specified by the International AIDS Society-USA mutations panel, with alterations as noted.¹⁶ The presence of at least 1 primary mutation (PR D30N, M46I, G48V, V82A, I84V, or L90M) was required for genotypic protease inhibitor (PI) resistance, while any mutation was used to define genotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) (RT M41L, E44D, K65R, D67N, any insertion at T69, K70R, L74V, V75T, V118I, Q151M, M184I/V, L210W, T215Y/F, and K219Q) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) (RT A98G, L100I, K103N, V106A, V108I, Y181C/I, Y188C/L/H, and G190A). In addition, the RT T215C/D/S/N mutations were included because they indicate previous resistance involving the RT T215Y mutation.¹⁷ For 213 participants, the presence of mutations was assessed by population sequencing of codons 3 to 99 of the protease gene and codons 38 to 247 of the reverse transcriptase reading frame by using the TRUGENE HIV-1 Genotyping Kit (Visible Genetics, Inc, Atlanta, Ga). For 12 individuals with limited specimen, a noncommercial method of automated cycle sequencing of the protease and reverse transcriptase reading frames was used.¹⁸

Information from sequencing reactions was assembled with OpenGene software (Visible Genetics, Inc) or Seqman (DNASTar, Madison, Wis) and proofread manually. Mixtures of sequences were reported if 2 or more bases had more than 20% relative peak

Figure 1. Genotypic and Phenotypic Resistance by Class of Antiretroviral Drugs by Calendar Year



All treated individuals received 3 or more antiretroviral agents. PI indicates protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.

Table 1. Participant Characteristics by Time Interval*

	1996	1997	1998	1999
Participants, No.	12	28	53	41
Men, No. (%)	10 (83.3)	24 (85.7)	50 (94.3)	37 (90.2)
Men who have sex with men, No. (%)	10 (83.3)	22 (78.6)	46 (86.8)	35 (85.4)
Age, mean (SD), y	34.8 (5.5)	34.2 (7.9)	35.4 (9.1)	35.5 (10.4)
Less sensitive optical density to cutoff ratio, median (IQR percentile)	0.51 (0.13-0.67)	0.04 (0.03-0.21)	0.16 (0.02-0.50)	0.26 (0.01-0.50)
Viral load, median (IQR percentile)	19 505 (2175-34 603)	14 457 (1723-69 185)	30 000 (4572-127 142)	59 483 (12 467-259 009)
CD4 cells, median, No. (IQR percentile)	515 (394-965)	533 (375-658)	510 (403-602)	483 (356-577)
CD4 cells, % (of CD3 cells) (IQR percentile)	31 (22-41)	28 (23-37)	30 (24-36)	31 (22-35)

*IQR indicates interquartile range.

height in the forward and reverse sequencing reactions. Consensus sequences from different individuals were aligned and manually edited, and neighbor-joining phylogenetic trees were used to seek evidence of laboratory contamination.

Phenotypic Assessment

Phenotypic drug-susceptibility testing was performed with the PhenoSense Assay (ViroLogic, Inc, South San Francisco, Calif).¹⁹ Viruses were defined as resistant if the fold change in IC₅₀ (inhibitory concentration, or the concentration of a drug that inhibits viral replication by 50%) was at least 1.7 for stavudine, didanosine, and zalcitabine; at least 4.5 for lamivudine, zidovudine, and abacavir; at least 10 for delavirdine, efavirenz, nevirapine, and lopinavir; and at least 4 for nelfinavir, amprenavir, saquinavir, indinavir, and ritonavir (N.S.H., written communication, January 2002). For abacavir, stavudine, didanosine, and lopinavir, the phenotypic cutoffs were levels of drug susceptibility above which there is detectable impairment in virologic response.²⁰⁻²² For NNRTIs, the 10-fold cutoff represents the upper limit of the normal range of biological variation,²³ below which virologic responses were normal in small clinical series.^{24,25} For other drugs, the phenotypic cutoffs were based on assay precision,¹⁹ biological variability,²³ and limited clinical experience. Phenotypic resistance defined by using cutoffs of 2.5 and 10 are also reported to allow comparison with prior reports.^{8,9}

Other Laboratory Assays

Plasma viral RNA load was measured with the Roche HIV-1 Amplicor Monitor assay (Roche Diagnostics, Branchburg, NJ), and CD4 cell counts were measured by using flow cytometry.

Statistical Analysis

Before analysis, the data were categorized by year of enrollment for convenience and to allow correlation with other epidemiologic information. For statistical analysis and reporting of resistant proportions, the calendar-year periods were collapsed into 3 intervals, 1996 and 1997, 1998 and 1999, and 2000 and 2001, which allowed primary resistance proportions to be estimated with greater precision in 3 periods. Comparisons with categorical variables throughout the study were evaluated with the Fisher exact test. Differences in continuous variables were evaluated with Kruskal-Wallis tests. Time trends in the prevalence of drug resistance were assessed with the Cochran-Armitage exact trend test. To ensure that dividing observations into time periods did not bias the results, the proportion resistant was also evaluated with logistic regression by using study enrollment date to predict the probability of resistance. Multiple logistic regression was used to determine whether any genotypic evidence of drug resistance was associated with the duration of HIV infection and CD4 cell count and whether primary resistance changed over time after these baseline factors were controlled. Viral load data were available from weekly time points

for the first 4 weeks and then monthly time points thereafter. Time to viral load suppression was evaluated with Kaplan-Meier survival analysis. All statistical tests were 2-tailed ($P < .05$). Data analyses were performed with SAS version 8.2 (SAS Institute, Cary, NC).

RESULTS

Cohort Characteristics

From June 10, 1996, through June 30, 2001, 243 participants were found to have evidence of recent HIV-1 infection (FIGURE 1). All of these participants were included in the study of primary drug resistance. Eighteen (7.4%) were excluded from the analysis because a drug-resistance genotype was unavailable from a point within 7 days of initiation of antiretroviral therapy. The reasons for an unavailable genotype included no specimen available ($n=9$) or a failed genotyping assay ($n=9$). The remaining 225 participants were divided according to the year they were identified. There were no significant differences over time in age, sex, risk group, CD4 cell count, CD4 percentage, or viral load (TABLE 1). The mean optical density to cutoff ratio in the less-sensitive EIA test¹⁵ fluctuated significantly in the first 2 years of the study but did not change significantly after 1997. Resistance determinations were obtained before any treatment in 215 (95.6%) participants and during the first 7 days of treatment in 10 (4.4%) persons. Genotypic analysis was based on the TRUGENE HIV-1 Genotyping Kit (Visible Genetics, Inc) in 213 persons (94.7%) and a noncommercial cycle sequencing assay in the remaining 12 (5.3%). The demographic characteristics of the overall sample were comparable to those of seroincident cases of HIV-1 in San Francisco as defined by an expert consensus panel in 1997.²⁶

Genotypic Analysis

Genotypic evidence of resistance was detected in 52 (23.1%) individuals (TABLE 2). The proportion with genotypic resistance to NRTIs varied significantly over time, decreasing from 25.0% (10/40) in 1996-1997 to 7.4% (7/


2000	2001	Total	P Value
62	29	225	
57 (91.9)	26 (89.7)	204 (90.7)	.66
56 (90.3)	25 (86.2)	194 (86.2)	.75
34.7 (8.1)	36.2 (6.5)	35.2 (8.4)	.96
0.15 (0.03-0.43)	0.05 (0.01-0.25)	0.16 (0.02-0.48)	.07
61 952 (11 498-187 336)	35 871 (10 057-187 041)	40 900 (6697-156 496)	.74
515 (365-695)	620 (456-810)	511 (383-661)	.32
30 (23-36)	32 (27-37)	30 (23-36)	.87

Table 2. Summary of Mutations Over Time

Drug Class	Mutation	No. (%)			P Value	
		1996-1997 (n = 40)	1998-1999 (n = 94)	2000-2001 (n = 91)	Trend*	Homogeneity†
Nucleoside reverse transcriptase inhibitor	Any	10 (25.0)	7 (7.4)	19 (20.9)	.90	.007
	Any of RT M41L, D67N, T69D, L210W, or K219Q	4 (10.0)	4 (4.2)	11 (12.1)	.42	.14
	RT M184V/I	4 (10.0)	2 (2.1)	7 (7.7)	.99	.07
	RT Y215Y/F	1 (2.5)	0	3 (3.3)	.52	.18
	RT Y215S/C/D/N	4 (10.0)	1 (1.1)	9 (9.9)	.57	.01
Nonnucleoside reverse transcriptase inhibitor	Any	0	6 (6.4)	12 (13.2)	.01	.02
	RT K103N	0	3 (3.2)	8 (8.8)	.02	.08
	Any of RT A98G, V106A, V108I, or G190A	0	3 (3.2)	5 (5.5)	.14	.35
Protease inhibitor	Any primary mutation	1 (2.5)	5 (5.3)	7 (7.7)	.25	.52
	PR D30N	0	0	1 (1.1)	.58	.58
	PR V82A	0	1 (1.1)	4 (4.4)	.12	.21
	PR 184V	0	0	2 (2.2)	.19	.49
	PR L90M	1 (2.5)	4 (4.2)	3 (3.3)	.99	.99
Any	Any	10 (25.0)	17 (18.1)	25 (27.4)	.58	.28
Any	Mutations affecting ≥ 2 classes of antiretrovirals	1 (2.5)	1 (1.1)	12 (13.2)	.004	.002
All	Mutations affecting all 3 classes of antiretrovirals	0	0	1 (1.2)	.58	.58

*Two-sided P value from Cochran-Armitage exact trend test.

†Two-sided P value from Fisher exact test.

Figure 2. Flow Diagram of the Analysis of Time to Virologic Suppression (Viral Load Less Than 500 Copies/mL)

Genotypic resistance was defined as any mutation associated with decreased susceptibility or poor virologic response to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) or any primary mutation associated with protease inhibitor (PI) resistance. Phenotypic drug resistance was defined by using susceptibility cutoff thresholds that have been associated with poor virologic response, when such information is available. These cutoffs ranged from 1.7 to 10.0, depending on the drug. Categories in the upper panels are not mutually exclusive, since viruses may be resistant to more than 1 drug class. Categories of number of drug classes affected in the lower panels are mutually exclusive.

94) in 1998-1999 and then increasing to 20.9% (19/91) in 2000-2001 (test for homogeneity, $P = .007$). The prevalence of genotypic resistance to PIs was 2.5% in 1996-1997 and 7.7% in 2000-2001 (trend test, $P = .25$). Genotypic resistance to NNRTIs increased steadily from 0% in 1996-1997 to 13.2% in 2000-2001 (trend test, $P = .01$). Genotypic resistance to 2 or more classes of antiretroviral drugs increased from 2.5% (1/40) in 1996-1997 to 13.2% (12/91) in 2000-2001 (trend test, $P = .004$). Only 1 (0.4%) of 225 recently infected individuals had genotypic resistance to all 3 classes of antiretroviral therapy. Plots of time trends by calendar year suggest rapid and recent increases in primary resistance to NNRTIs, while resistance to PIs appeared earlier and has remained more stable (FIGURE 2).

Phenotypic Analysis

Phenotypic drug susceptibility testing was attempted in all 225 participants with completed genotypic analysis and was successful in 210 (93.3%) (TABLE 3). The proportion of new in-

Table 3. Summary of Phenotypic Susceptibility Over Time*

Drug Class	Susceptibility	No. (%)			P Value	
		1996-1997 (n = 38)	1998-1999 (n = 91)	2000-2001 (n = 81)	Trend†	Homogeneity‡
Nucleoside reverse transcriptase inhibitor (NRTI)	Any NRTI resistance defined by using clinical cutoffs (1.7- to 4.5-fold)	8 (21.0)	3 (3.3)	5 (6.2)	.03	.004
	>2.5-fold increase in IC ₅₀ to any RTI	5 (13.1)	4 (4.4)	6 (7.4)	.46	.21
	>10-fold increase in IC ₅₀ to any RTI	3 (7.9)	0	4 (4.9)	>.99	.02
Nonnucleoside reverse transcriptase inhibitor (NNRTI)	Any NNRTI resistance defined by using clinical cutoffs (10-fold)	0	4 (4.4)	8 (9.9)	.02	.07
	>2.5-fold increase in IC ₅₀ to any NNRTI	9 (23.7)	21 (23.1)	22 (27.2)	.66	.83
Protease inhibitor (PI)	Any PI resistance defined by using clinical cutoffs (4-fold)	1 (2.6)	2 (2.2)	5 (6.2)	.32	.45
	>2.5-fold increase in IC ₅₀ to any PI	4 (10.5)	8 (8.8)	13 (16.0)	.31	.33
	>10-fold increase in IC ₅₀ to any PI	1 (2.6)	0	5 (6.2)	.16	.03
Any	Clinical resistance to ≥1 drug class	8 (21.0)	9 (9.9)	13 (16.0)	.79	.21
Any	Clinical resistance to ≥2 drug classes	1 (2.6)	0	4 (4.9)	.35	.10
All	Clinical resistance to all 3 drug classes	0	0	1 (1.2)	.57	.57

*IC₅₀ indicates the inhibitory concentration, or the concentration of the drug that inhibits viral replication by 50%.

†Two-sided P value from Cochran-Armitage exact trend test.

‡Two-sided P value from Fisher exact test.

fections with NNRTI resistance increased over time from 0 in 1996-1997 to 9.9% in 2000-2001 (Figure 2) (trend test, $P=.02$). The prevalence of primary phenotypic resistance to PIs was 2.6% in 1996-1997 and 6.2% in 2000-2001 (trend test, $P=.32$). Primary phenotypic resistance to NRTIs decreased throughout the study from 21.0% in 1996-1997 to 6.2% in 2000-2001 (trend test, $P=.03$). The proportion of individuals with decreased susceptibility to 2 or more classes of antiretroviral agents was 2.6% in 1996-1997 and 4.9% in 2000-2001 (trend test, $P=.35$). Phenotypic resistance to all 3 classes of antiretroviral agents occurred in only 1 person, who enrolled in 2000.


Virologic Responses to PI-Containing Therapy

To determine whether primary resistance was associated with delayed virologic response, we analyzed the time to virologic suppression, defined as the first plasma viral RNA concentration less than 500 copies/mL. This analysis included only the subset of 141 (62.7%) participants who initiated antiretroviral therapy, which consisted of NRTIs

and a PI in 139 participants, NRTIs and an NNRTI in 1 individual, and 3 NRTIs in 1 individual (Figure 2). Participants were classified according to whether there was genotypic resistance to any antiretroviral drug class used. If therapy was stopped for any reason, observations were excluded from the analysis after the last treatment date. Resistance testing was not used to select the initial drug regimen in any participant. Median time to viral load suppression was longer in 30 individuals with genotypic resistance compared with 111 without resistance (Figure 3, 12 weeks vs 5 weeks; log-rank test, $P=.02$). One of these individuals was infected with HIV-1 resistant to NRTIs and PIs and had persistent plasma viral load after 6 months of combination therapy, as reported earlier.⁴

Baseline Correlates of Genotypic Drug Resistance


The detection of primary genotypic resistance was more frequent among individuals who were infected for shorter periods, as estimated by the less-sensitive EIA optical density to cutoff ratio (Spearman rank correlation, $P=.02$). The detection of genotypic resistance

Figure 3. Time to Viral Load Suppression Below 500 Copies/mL During Treatment

Participants were categorized into resistance groups (Figure 2). Viral load in all treated groups was assessed weekly and censored from the analysis for any report of stopping therapy. Time to viral suppression was longer among participants with any evidence of resistance to the regimen used ($P=.02$).

was 28.8% among those in the first quartile of duration of infection, 27.4% among the second quartile, 19.2%

Figure 4. Viral Load, CD4 Cell Count, and Genotypic Drug Resistance in Drug-Naïve Recently Infected Individuals



The whiskers represent the entire range, the boxes represent the interquartile range (25% to 75%), and the black horizontal lines within the boxes represent the median values. The median viral load in individuals with genotypic drug resistance was not significantly lower than that of individuals with wild-type HIV-1 ($P = .71$). The CD4 cell counts were higher in individuals with drug-selected variants ($P = .03$), even after duration of infection, as indicated by the less-sensitive enzyme immunoassay optical density, was controlled.

among the third quartile, and 11.5% among the quartile infected for the longest period (trend test, $P = .01$). These indexes of the duration of infection were not associated with year of enrollment (Spearman rank correlation, $P = .64$). The initial plasma viral RNA load was highly variable, most likely because of rapid changes in viremia that occur during recent HIV-1 infection (FIGURE 4). There was no difference in initial plasma viral load between the individuals with resistant virus and those with sensitive virus ($P = .71$). In contrast, baseline CD4 cell counts and CD4 cell percentages were significantly higher among individuals infected with resistant HIV-1

($P = .02$ and $P = .04$, respectively). Multivariate logistic regression indicated that a higher CD4 cell count was independently associated with resistant HIV-1 ($P = .03$) after duration of infection was controlled.

COMMENT

The proportion of recent infections that involve NNRTI resistance increased rapidly in this serial cross-sectional survey. Treatment with NNRTIs became more common in late 1998, when clinical trial results indicated that virologic outcomes during treatment with an NNRTI were comparable with those of PI-based treatment.²⁷ Increases in primary NNRTI resistance observed after 1999 in this study likely reflect more prevalent use of NNRTIs in the previous year. A study of primary drug resistance in the United Kingdom also reported trends toward increasing primary genotypic resistance, which included NNRTI resistance in 3 of 26 (11.5%) individuals in 2000 and none of 22 individuals in 1997 through 1999.²⁸ Similarly, cases of primary PI resistance appeared in San Francisco⁴ and Geneva¹⁰ after approximately 1 year of widespread PI exposure.

In contrast to primary NNRTI resistance, primary PI resistance remained relatively stable from 1997 through 2001 (Figure 2). The transmission of HIV-1 resistance to all 3 available classes of antiretroviral therapy continues to be rare, occurring in only 1 of 225 (0.4%) individuals in this series. In contrast, the prevalence of 3-class drug resistance among 268 drug-experienced participants presenting for clinical resistance testing in our laboratory in San Francisco was 14.3% during 2000-2001 (data not shown). The infrequent transmission of 3-class multidrug resistance in our series from San Francisco and elsewhere^{2,8-10} may reflect the poor replication capacity of these extensively mutated viruses.²⁹ Just as lower viral load in untreated individuals was associated with decreased sexual transmission,³⁰ so too the lower viral load typically observed during multidrug resistant viremia^{13,31} may diminish the frequency of

transmission of these viruses. In contrast, NNRTI-resistant viruses demonstrate relatively high levels of plasma viral load during drug failure^{32,33} and may prove to have concordantly preserved capacity for transmission.

The changing proportions of NRTI-resistant HIV-1 over time may reflect changing virologic outcomes among persons who transmit HIV-1. Before 1996, antiretroviral therapy consisted of single or dual NRTIs, which typically lead to viremia with drug-resistant HIV-1 in the majority of patients. Transmission of NRTI-resistant viruses in San Francisco may have decreased in 1998-1999 as treated populations changed to more active regimens that contain PIs, NNRTIs, or both. Trends toward decreasing primary resistance to nucleoside analogues have been observed in other settings as well.^{2,34} Since 1998, genotypic resistance testing has indicated that the proportion of NRTI-resistant cases is increasing once again, although this trend was not confirmed by phenotypic analysis. Increases of genotypic NRTI resistance possibly reflect restored infectiousness of extensively antiretroviral-experienced individuals. Alternatively, the observed changes in primary resistance prevalence could reflect changes in risk behavior, which were not assessed in this study. Further, although demographic characteristics did not change throughout the course of this study, changes in referral patterns may have occurred and contributed to the observed trends in resistance prevalence.

Drug-resistance testing is recommended for persons failing antiretroviral therapy and for HIV-1-infected pregnant women.³⁵⁻³⁷ For persons with primary HIV infection, the International AIDS Society-USA³⁵ and Department of Health and Human Services³⁶ guidelines indicate that resistance testing should be considered, and the EuroGuidelines group³⁷ recommends testing. Our data support the use of resistance testing in recently infected persons in settings where antiretroviral use is widespread. In this sample of recently infected individuals, primary

drug resistance was found to have high prevalence and was predictive of slower virologic responses. Although most treated individuals with primary drug resistance eventually achieved viral loads less than 500 copies/mL, the delay in virologic response likely reflects decreased drug activity. Whether primary resistance will worsen long-term virologic and clinical outcomes requires further study. Nevertheless, the growing prevalence of primary NNRTI resistance and the substantial prevalence of primary PI and NRTI resistance suggest that resistance testing has a role in guiding antiretroviral use in recently infected persons.

Overall, the prevalence of primary phenotypic resistance was less than the prevalence of genotypic resistance, partly because genotypes that indicate prior drug resistance but do not affect current susceptibility, such as the RT T215C/D/S/N mutation, were included. In addition, the genotyping assay detected some mixtures of resistant and sensitive HIV-1 that had normal susceptibility. Finally, the susceptibility cutoff values used to define phenotypic resistance have not been defined for all drugs, and conservatively high levels were selected when there was uncertainty.

The higher average CD4 cell count among individuals infected with drug-resistant HIV-1 suggests that resistant isolates may cause less initial injury to the immune system, possibly because of decreased viral replication capacity³⁸ or decreased tropism for tissues involved in T-cell production, such as the thymus.³⁹ Relatively preserved CD4 cell counts and slower T-cell turnover have been observed in individuals during multidrug-resistant viremia.^{11,40} These partial CD4 cell-count responses require continued use of antiretroviral therapy,²⁹ which maintains partial viral load suppression⁴¹ and selection for drug-resistant HIV-1 that has diminished replication capacity.²⁹ Our observations indicate that drug-resistant HIV-1 infection is associated with higher CD4 cell counts in drug-naïve persons as well, providing additional

evidence that CD4 cell-count sparing may be due to viral factors such as diminished replication capacity.

Primary HIV-1 drug resistance indicates that the risks of antiretroviral therapy extend beyond the treated individual to uninfected populations.^{2,4,9,10,42} Indeed, primary resistance indicates triple failure of the health care system, including failure of drug treatment to control viral replication in the source partner, failure of behavioral prevention in the source partner receiving treatment, and failure of behavioral prevention in the recently infected person. Intervention to minimize transmission of drug-resistant HIV-1 will require physician education to improve prescribing, more tolerable drug regimens, counseling to promote adherence, and more effective prevention programs targeted to infected and uninfected persons. Prevention programs specifically linked to treatment may serve to ensure that the clinical and epidemiological benefits of widespread antiretroviral therapy are not offset by increases in risk behavior and the transmission of drug-resistant HIV-1.^{43,44}

Author Affiliations: Gladstone Institute of Virology and Immunology (Drs Grant and Liegler and Ms Warmerdam), Positive Health Program, San Francisco General Hospital (Drs Grant, Hecht, Liu, and Kahn), Center for AIDS Prevention Studies (Dr Chesney), Department of Medicine, University of California, San Francisco (Drs Grant, Hecht, Liu, Busch, and Kahn), Blood Centers of the Pacific (Dr Busch), San Francisco; and ViroLogic, South San Francisco, Calif (Drs Petropoulos and Hellmann).

Financial Disclosures: Drs Hellmann and Petropoulos are employees of ViroLogic Inc, commercial provider of PhenoSense HIV, the assay used to measure HIV-1 drug susceptibility in this study. Dr Kahn is a paid consultant of ViroLogic Inc. Dr Grant is a paid consultant of Visible Genetics Inc, and has received honoraria and research support from ViroLogic and Visible Genetics. He also has received honoraria for speaking at educational programs supported by ViroLogic, Visible Genetics, GlaxoSmithKline, Bristol-Myers Squibb, Roche Pharmaceuticals, and Agouron and he directs a nonprofit academic laboratory that has provided services for clinical research supported by grants to the University of California from Merck, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Abbott, Agouron, Gilead, Visible Genetics, Oxo-Chemie, and Chiron. Dr Chesney has received honoraria for speaking at educational programs supported by Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Agouron. Dr Kahn has received honoraria for speaking at educational programs supported by Merck, Bristol-Myers Squibb, Agouron, ViroLogic, GlaxoSmithKline, Abbott, Oxo-Chemie, and Chiron. These companies and Gilead Sciences, Immune Response Corporation, DuPont Pharmaceuticals, and GeneLabs have previously provided funds to the University of California to support Dr Kahn's research activities.

Author Contributions: Study concept and design: Grant, Hecht, Kahn.

Acquisition of data: Grant, Hecht, Warmerdam, Liegler, Petropoulos, Chesney, Busch, Kahn.

Analysis and interpretation of data: Grant, Hecht, Warmerdam, Liu, Hellmann, Kahn.

Drafting of the manuscript: Grant, Hecht, Petropoulos, Kahn.

Critical revision of the manuscript for important intellectual content: Grant, Hecht, Warmerdam, Liu, Liegler, Hellmann, Chesney, Busch, Kahn.

Statistical expertise: Grant, Hecht, Liu.

Obtained funding: Grant, Hecht, Chesney, Busch, Kahn.

Administrative, technical, or material support: Grant, Hecht, Warmerdam, Liegler, Hellmann, Chesney, Busch.

Study supervision: Grant, Hecht, Liegler, Petropoulos.

Funding/Support: This work was supported by the Gladstone Institute of Virology and Immunology and grants from the Centers for Disease Control and Prevention (U64/CCU913941), the UCSF Center for AIDS Research (P30 MH59037), the University of California Universitywide AIDS Research Program (CC97-0962 and CC99-SF-001), and the National Institutes of Health (AIEDP AI 41531 and MH64384-01).

Acknowledgment: We thank Jacqueline Javier, MS, MT, Birgit Drews, BS, Timothy Schmidt, BS, MT, and Kenneth Plamenco, MD, for outstanding technical support. We are indebted to the ViroLogic Clinical Reference Laboratory for performing the phenotypic analysis and Visible Genetics, Inc, for provision of TRUGENE HIV-1 Resistance Kits.

REFERENCES

1. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts [letter]. *AIDS*. 1994;8:1013-1014.
2. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. *AIDS*. 2001;15:2287-2292.
3. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. *J Infect Dis*. 1994;169:411-415.
4. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. *N Engl J Med*. 1998;339:307-311.
5. Ippolito G, Del Poggio P, Arici C, et al. Transmission of zidovudine-resistant HIV during a bloody fight [letter]. *JAMA*. 1994;272:433-434.
6. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. *J Infect Dis*. 1997;175:1502-1506.
7. Veenstra J, Schuurman R, Cornelissen M, et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. *Clin Infect Dis*. 1995;21:556-560.
8. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. *JAMA*. 1999;282:1135-1141.
9. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. *JAMA*. 1999;282:1142-1149.
10. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. *Lancet*. 1999;354:729-733.
11. Deeks S, Hecht F, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. *AIDS*. 1999;13:F35-F43.

12. Roland ME, Martin JN, Grant RM, et al. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. *J Infect Dis*. 2001;184:1608-1612.
13. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. *J Infect Dis*. 2000;181:946-953.
14. Ledergerber B, Egger M, Opravil M, et al, for the Swiss HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Lancet*. 1999;353:863-868.
15. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. *JAMA*. 1998;280:42-48.
16. D'Aquila RT, Schapiro J, Brun-Vezinet F, et al. Update on drug resistance mutations in HIV-1. *HIV Med*. 2001;9:31-33.
17. Yerly S, Rakik A, De Loes SK, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. *J Virol*. 1998;72:3520-3523.
18. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. *J Virol*. 1998;72:5303-5306.
19. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. *Antimicrob Agents Chemother*. 2000;44:920-928.
20. Lanier ER, Hellmann NS, Scott J, et al. Determination of a clinically relevant phenotypic resistance "cutoff" for Abacavir using the PhenoSense assay (abstract 254). Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 5-6, 2001; Chicago, Ill.
21. Kempf D, Brun S, Rode R, et al. Identification of clinically relevant phenotypic and genotypic break-points for AbT-378/R in multiple PI-experienced, NNRTI-naïve patients (abstract 89). Paper presented at: 4th International Workshop on HIV Drug Resistance and Treatment Strategies, June 28-July 1, 2000; Sitges, Spain.
22. Haubrich R, Keiser P, Kemper C, et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy (abstract 80). Paper presented at: 5th International Workshop on HIV Drug Resistance and Treatment Strategies; June 4-8, 2001; Scottsdale, Ariz.
23. Harrigan PR, Montaner JSG, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. *AIDS*. 2001;15:1671-1677.
24. Bachelier L, Ploughman L, Hertogs K, Larder B. Impact of baseline nnRTI resistance on the efficacy of efavirenz combination therapy in nnRTI therapy-naïve patients (study DMP 266-006). Paper presented at: 4th International Workshop on HIV Drug Resistance and Treatment Strategies; June 28-July 1, 2000; Sitges, Spain.
25. Harrigan PR, Verbiest W, Larder B, et al. Impact of moderate decreases in baseline nnRTI susceptibility on response to antiretroviral therapy (abstract 86). Paper presented at: 4th International Workshop on HIV Drug Resistance and Treatment Strategies; June 28-July 1, 2000; Sitges, Spain.
26. McFarland W, Kellogg T, Nieri G, et al. *San Francisco HIV Epidemiology Report: Data Available to 1998*. San Francisco, Calif: San Francisco Department of Public Health; 1998.
27. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus didanosine, and didanosine plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. *N Engl J Med*. 1999;341:1865-1873.
28. Porter K, Pillay D, Cane P, et al. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. *BMJ*. 2001;322:1087-1088.
29. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med*. 2001;344:472-480.
30. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1: Rakai Project Study Group. *N Engl J Med*. 2000;342:921-929.
31. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. *J Infect Dis*. 1999;180:659-665.
32. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase: L-697,661 Working Group. *N Engl J Med*. 1993;329:1065-1072.
33. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial: Italy, the Netherlands, Canada and Australia Study. *JAMA*. 1998;279:930-937.
34. Goudsmit J, Jan Weverling G, van der Hoek L, et al. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. *AIDS*. 2001;15:2293-2301.
35. Hirsch M, Brun-Veninet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. *JAMA*. 2000;283:2417-2426.
36. Fauci AS, Bartlett JG, Goosby EP, Kates J. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents [HIV/AIDS Treatment Information Service Web site]. Available at: <http://www.hivatis.org/trtgdlns.html>. Accessed January 7, 2002.
37. Miller V, Vandamme AM, Loveday C, et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. *AIDS*. 2001;15:309-320.
38. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. *J Virol*. 1998;72:7632-7637.
39. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. *Nat Med*. 2001;7:712-718.
40. Deeks SG, Hoh R, Grant RM, et al. CD4(+) T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. *J Infect Dis*. 2002;185:315-323.
41. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. *AIDS*. 2002;16:201-207.
42. Boden D, Hurley A, Zhang L, et al. Prevalence of HIV-1 drug resistance mutations in 80 newly infected individuals [abstract]. *Antivir Ther*. 1999;4(suppl 1):85.
43. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. *Science*. 2000;287:650-654.
44. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. *Nat Med*. 2001;7:1016-1020.